Disclosure of Payments to Healthcare Professionals

Our collaborations with healthcare professionals always aim to benefit patients, improve medical practices and patient care. 
Activities can range from clinical research to exchanges on how new medicines fit into patient pathway. 
We believe that a more open transparent relationship strengthens the basis for collaboration and is in the best interest of patients and all health stakeholders.
For this reason, we are committed to disclose our interactions with healthcare professionals and organizations through the Disclosure Code de l’EFPIA.

 

Austria

 Public disclosure   201920202021,

 

 

Belgium

 

Bulgaria

Public disclosure 201920202021

 

Cyprus

Public disclosure 20192021,
No Transfer of Value in 2020

 

Czech Republic 

Public disclosure   2019 , 2021

No Transfer of Value in 2020

 
Denmark

Public disclosure   201920202021

 

Estonia

No Transfer of Value in 2019, 2020, 2021

 

Finland

Public disclosure 201920202021,

 
France

 

Germany

 

Greece

Greece PFD report 2019/Greece PFMS report 2019/ Pierre Fabre Greek Crossborder ToVs 2019

Report PFD 2020/ Report PFMS 2020

PFMS Italy Greek Crossborder 2020 /Pierre Fabre Corporate Greek Crossborder 2020

Greece PFD report 2021/Greece PFMS report 2021/ Pierre Fabre Greek Crossborder ToVs 2021

 

Hungary

Public disclosure 20192021
No Transfer of Value in 2020

 

Italy

 

Ireland

 

Lithuania


No Transfer of Value in  2019, 2020,2021
 

Malta

No Transfer of Value in 2019, 2020, 2021

 

Netherlands 

 

Norway

Public disclosure  2019, 20202021

 
Poland

Public disclosure HCP    2019, 20202021
Public disclosure  HCO  201920202021
Public disclosure R&D  2019,  2020 , 2021

 

Portugal

Romania

No Transfer of Value in 2019, 2020, 2021


Russia

 

Slovak republic

Public disclosure 20192020, 2021

 

Spain

Sweden

Public disclosure 201920202021


Switzerland

Public disclosure   2019, 20202021

 

Ukraine

No Transfer of Value in 2019, 2020, 2021
 

United Kingdom



 

DISCLOSURE METHODOLOGY PIERRE FABRE PHARMACEUTICALS TOV 2021

  • The publication provided through this section is made in accordance with the Company Self-Certification.
  • Following European legislation on data privacy, recipients of published transfers of value have a right to access and correct personal data concerning them, which is exercisable by e-mail: transparency.compliance@pierre-fabre.com